Preclinical Data Viking presented 2 posters (#206 3 and #207 4 ) with preclinical data from a series of internally developed dual agonists of the GLP-1 and GIP receptors at ObesityWeek 2021 (November)
Why Might GLP-1 Drugs Affect Bone Health
[DOI] [PMC free article] [PubMed] [Google Scholar] 81.Fernndez-Castaeda A., Lu P., Geraghty A.C., Song E., Lee M.H., Wood J., ODea M.R., Dutton S., Shamardani K., Nwangwu K., Mancusi R., Yaln B., Taylor K.R., Acosta-Alvarez L., Malacon K., Keough M.B., Ni L., Woo P.J., Contreras-Esquivel D., Toland A.M.S., Gehlhausen J.R., Klein J., Takahashi T., Silva J., Israelow B., Lucas C., Mao T., Pea-Hernndez M.A., Tabachnikova A., Homer R.J., Tabacof L., Tosto-Mancuso J., Breyman E., Kontorovich A., McCarthy D., Quezado M., Vogel H., Hefti M.M., Perl D.P., Liddelow S., Folkerth R., Putrino D., Nath A., Iwasaki A., Monje M
Pack double: Bring twice as many supplies as you think youll need, split between your carry-on and personal item
Tonum reports human clinical trials showing about 10.4% average weight loss over six months, which is notable for an oral supplement
While no differences in the risk of HSV or HZ infections were observed between GLP-1RA and SGLT-2i in patients with HbA1c 7%, the significantly increased risk of HSV infections associated with GLP-1RA compared to DPP-4i underscores the need for periodic monitoring
